杜氏肌肉发育不良:将当前的临床实践与未来的治疗和诊断视野相结合
Costanza Montagna1, Emiliano Maiani1,2, Luisa Pieroni1,2
1Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy.
International journal of molecular sciences
|July 29, 2025
概括
杜恩肌肉发育不良 (DMD) 治疗正在推进,重点是基因疗法和早期诊断,以改善患者的治疗结果. 目前的研究探讨了新的策略,以恢复缩蛋白和减缓疾病的进展,以改善生活质量.
科学领域:
- 遗传学和分子生物学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜氏肌肉发育不良 (DMD) 是一种严重的X链遗传疾病,导致肌肉逐渐退化.
- 双基因的突变是DMD的主要原因,导致功能性双蛋白缺乏.
- 尽管了解DMD病理生理学的进展,但治疗方法仍然难以捉摸.
研究的目的:
- 为杜氏肌肉发育不良症提供当前和新兴治疗策略的最新审查.
- 强调早期诊断和基因查在管理DMD中的关键作用.
- 突出诊断技术的进步及其与精密疗法的整合.
主要方法:
- 关于杜恩肌肉衰竭治疗的当前文献的综述.
- 分析新兴的治疗方法,包括基因疗法,基因编辑和药理干预.
- 评估在产前和产后检测和遗传查方面的诊断进展.
主要成果:
- 一些治疗途径正在调查中,包括反感性寡核酸,基因疗法,基因编辑,皮质类固醇和HDAC抑制剂.
- 早期诊断和基因查对于及时干预和改善预后至关重要.
- 诊断技术的创新正在促进DMD的个性化医疗方法.
结论:
- 新兴的疗法旨在恢复双氨酸表达或减轻DMD的进展.
- 个性化医学,将精确疗法与先进诊断相结合,为DMD改善结果提供了希望.
- 持续的研究和早期检测是提高DMD患者生活质量的关键.
相关概念视频
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle
1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Cystic Fibrosis: Management
224
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
224
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23


